This bill would direct the Secretary of Health and Human Services to review certain medical devices manufactured in the People’s Republic of China for potential cybersecurity vulnerabilities. The goal is to identify devices that could be exposed to hacking, data theft, unauthorized remote access, or other digital threats that could affect patients and providers. It would primarily affect device manufacturers, hospitals, clinics, and patients who rely on connected medical equipment. The bill does not create a new medical program; it focuses on federal review and oversight of cybersecurity risk in a specific class of devices.
What This Bill Does
- Directs HHS to review certain medical devices manufactured in the People’s Republic of China
- Focuses on potential cybersecurity issues, including risks tied to connected or networked devices
- Targets a narrow class of medical equipment rather than the broader healthcare system
- Places the bill in the Senate Health, Education, Labor, and Pensions Committee
Who This Bill Affects
For most people, this bill would have little immediate day-to-day effect. If you use a connected medical device, receive care in a hospital system that purchases such equipment, or work for a manufacturer or provider, the bill could lead to more cybersecurity review, more procurement caution, and possibly higher compliance costs that are eventually reflected in device pricing or purchasing decisions. It is most likely to matter indirectly through safer devices and stricter vetting rather than through direct benefits or costs to the general public.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patient safety advocates They would argue that medical devices should be tested for cyber vulnerabilities before they can jeopardize care or expose sensitive data. A federal review can help identify hidden risks that hospitals or patients cannot easily detect on their own.
- Hospitals and health-system security teams They may support clearer federal scrutiny because it can strengthen procurement standards and reduce the chance that a compromised device disrupts clinical operations. Centralized review can also create more consistent expectations across the industry.
- Domestic medical-device manufacturers They may see the bill as a way to reward stronger security practices and level the playing field for companies that invest in cybersecurity. It could make buyers more attentive to security quality, not just price and features.
- Medical-device importers and distributors They may argue the review could add delays and paperwork to purchasing and approval processes, especially for devices already cleared for clinical use. That could slow access to lower-cost equipment and complicate supply chains.
- Hospitals and clinics with tight budgets They could worry that extra review requirements will increase compliance costs and eventually raise prices for devices. Smaller providers may also have less capacity to evaluate substitutions if a product is flagged.
- Manufacturers with overseas production chains They may contend that broad scrutiny of devices manufactured in China risks sweeping in safe products and imposing costs based on geography rather than demonstrable security problems. They may also fear that new federal review standards create uncertainty for global sourcing.
Key Implications
-
““review certain medical devices manufactured in the People’s Republic of China””
This directs federal attention toward a specific set of imported products. In practice, it could prompt more security vetting before some devices are purchased or used in U.S. healthcare settings.
-
““for potential cybersecurity issues””
The focus is not just on physical safety or clinical performance, but on digital vulnerabilities. That means software, connectivity, remote access, and data-security features become central to how the devices are assessed.
-
““Secretary of Health and Human Services””
HHS would be the lead federal agency handling the review, which gives the department authority to shape guidance and scrutiny in the healthcare technology market.
-
““and for other purposes””
This standard clause allows related administrative or implementation provisions to be included, such as follow-up reporting or coordination with other federal health and security officials.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- S 4939
- Congress
- 119th Congress
- Official title
- A bill to require the Secretary of Health and Human Services to review certain medical devices manufactured in the People's Republic of China for potential cybersecurity issues, and for other purposes.
- Policy area
- Healthcare
- Latest action
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (June 24, 2026)
- Last updated
- June 25, 2026
Latest Status
June 24, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.